Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 77.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 380,103 shares of the medical research company’s stock after buying an additional 166,403 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Edwards Lifesciences were worth $28,139,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in EW. Wellington Management Group LLP raised its holdings in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. State Street Corp grew its stake in shares of Edwards Lifesciences by 1.0% during the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after purchasing an additional 256,538 shares in the last quarter. Geode Capital Management LLC increased its holdings in Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after buying an additional 284,918 shares during the last quarter. Fisher Asset Management LLC raised its stake in Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after buying an additional 696,965 shares in the last quarter. Finally, Jennison Associates LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $555,939,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on EW shares. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Barclays increased their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Truist Financial reissued a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $68.52 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $40.28 billion, a price-to-earnings ratio of 9.83, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The firm’s fifty day moving average price is $71.92 and its 200 day moving average price is $70.34. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares in the company, valued at approximately $1,569,414.24. The trade was a 1.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,303 shares of company stock valued at $3,255,356. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.